...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients
【24h】

Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients

机译:钙通道阻滞剂和利尿剂与血管紧张素II受体阻滞剂联合使用对高血压患者中枢主动脉压的差异作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The aim of this study was to compare the effects between calcium channel blockers and diuretics when used in combination with angiotensin II receptor blocker on aortic systolic blood pressure (BP) and brachial ambulatory systolic BP. We conducted a prospective, randomized, open-label, blinded end point study in 207 hypertensive patients (mean age: 68.4 years). Patients received olmesartan monotherapy for 12 weeks, followed by additional use of azelnidipine (n=103) or hydrochlorothiazide (n=104) for 24 weeks after randomization. The central BP by radial artery tonometry, aortic pulse wave velocity, and ambulatory BP were assessed at baseline and 24 weeks later. After adjustment for baseline covariates, the extent of the reduction in central systolic BP in the olmesartan/azelnidipine group was significantly greater than that in the olmesartan/hydrochlorothiazide group (the between-group difference was 5.2 mm Hg; 95% CI: 0.3 to 10.2 mm Hg; P =0.039), whereas the difference in the reduction in brachial systolic BP between the groups was not significant (2.6 mm Hg; 95% CI: ?2.2 to 7.5 mm Hg; P =0.29). The aortic pulse wave velocity showed a significantly greater reduction for the olmesartan/azelnidipine combination than for the olmesartan/hydrochlorothiazide combination (0.8 m/s; 95% CI: 0.5 to 1.1 m/s; P <0.001) after adjustment for covariates. The extent of the reduction in brachial ambulatory systolic BP was similar between the groups. These data showed that the combination of olmesartan (20.0 mg) and azelnidipine (16.0 mg) had a more beneficial effect on central systolic BP and arterial stiffness than the combination of olmesartan (20.0 mg) and hydrochlorothiazide (12.5 mg), despite the lack of a significant difference in brachial systolic BP reduction between the 2 treatments.
机译:这项研究的目的是比较钙通道阻滞剂和利尿剂与血管紧张素II受体阻滞剂联合使用时对主动脉收缩压(BP)和肱动脉动态收缩压的影响。我们对207位高血压患者(平均年龄:68.4岁)进行了一项前瞻性,随机,开放标签,盲目的终点研究。患者接受奥美沙坦单一疗法治疗12周,然后在随机分组后24周再使用阿兹地平(n = 103)或氢氯噻嗪(n = 104)。在基线和24周后,通过radial动脉眼压计,主动脉脉搏波速度和动态血压评估中心血压。调整基线协变量后,奥美沙坦/氮卓尼平组中收缩压的下降幅度明显大于奥美沙坦/氢氯噻嗪组(组间差异为5.2 mm Hg; 95%CI:0.3)至10.2 mm Hg; P = 0.039),而两组之间的肱动脉收缩压降低的差异不明显(2.6 mm Hg; 95%CI:≤2.2至7.5 mm Hg; P = 0.29)。调整协变量后,与组合奥美沙坦/氢氯噻嗪组合相比,奥美沙坦/氮卓尼平的主动脉脉搏波速度明显降低(0.8 m / s; 95%CI:0.5至1.1 m / s; P <0.001) 。两组之间肱动脉动态收缩压降低的程度相似。这些数据表明,尽管缺乏奥美沙坦(20.0 mg)和氢氯噻嗪(20.0 mg)的组合,奥美沙坦(20.0 mg)和阿兹地平(16.0 mg)的组合对中央收缩期血压和动脉僵硬的影响更明显。两种治疗之间的肱动脉收缩压降低有显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号